Point72 Middle East FZE’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-56,300
Closed -$2.89M 187
2023
Q4
$2.89M Sell
56,300
-35,100
-38% -$1.84M 0.09% 316
2023
Q3
$5.3M Buy
91,400
+18,500
+25% +$1.13M 0.17% 153
2023
Q2
$4.66M Buy
72,900
+41,500
+132% +$2.78M 0.13% 198
2023
Q1
$2.18M Sell
31,400
-120,400
-79% -$8.49M 0.07% 313
2022
Q4
$10.9M Buy
+151,800
New +$11.4M 0.48% 23

Other funds holding BMY

Point72 Middle East FZE's BMY Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 102,444 shares — an estimated $6.28M sold.

Point72 Middle East FZE first reported a position in BMY in Q2 2023 and held it in 1 quarter. The position peaked at $6.55M in Q2 2023. 2,388 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 102,444 Bristol-Myers Squibb shares in Q3 2023, an estimated $6.28M.
  • Point72 Middle East FZE first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Bristol-Myers Squibb position peaked at $6.55M in Q2 2023.
  • 2,388 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.